1. Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer
   Anne E. Lykkesfeldt et al, 2018, Acta Oncologica CrossRef
2. Decreased ER dependency after acquired resistance to CDK4/6 inhibitors
   Masafumi Iida et al, 2020, Breast Cancer CrossRef
3. Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers
   Marianne Hauglid Flågeng et al, 2017, The Journal of Steroid Biochemistry and Molecular Biology CrossRef
4. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells
   Belinda J. Petri et al, 2021, Cancer Letters CrossRef
5. PEGylated Protamine Letrozole Nanoparticles: A Promising Strategy to Combat Human Breast Cancer via MCF-7 Cell Lines
   Muhammad Tafhim Khan et al, 2022, BioMed Research International CrossRef
6. Natural products as drug candidates for breast cancer (Review)
   Nitin Telang, 2023, Oncology Letters CrossRef
7. Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells
   Stine Hole et al, 2015, Breast Cancer Research and Treatment CrossRef
8. Natural phytochemicals as testable therapeutic alternatives for HER‑2‑enriched breast cancer (Review)
   Nitin Telang, 2020, World Academy of Sciences Journal CrossRef
9. Synthesis of novel forskolin isoxazole derivatives with potent anti-cancer activity against breast cancer cell lines
   Srinivas Burra et al, 2017, Bioorganic & Medicinal Chemistry Letters CrossRef
10. Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients
    Karina G. Thomsen et al, 2015, Breast Cancer Research and Treatment CrossRef
11. Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells
    Derek F. Amanatullah et al, 2017, Breast Cancer Research CrossRef
12. Partitioning of cancer therapeutics in nuclear condensates
    Isaac A. Klein et al, 2020, Science CrossRef
13. MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
    Sanne Løkkegaard et al, 2021, npj Breast Cancer CrossRef
14. Acquired resistance to aromatase inhibitors: where we stand!
    Tiago Vieira Augusto et al, 2018, Endocrine-Related Cancer CrossRef
15. The Divergent Effects of Ovarian Steroid Hormones in the MCF-7 Model for Luminal A Breast Cancer: Mechanistic Leads for Therapy
    Nitin T. Telang, 2022, International Journal of Molecular Sciences CrossRef
16. Modelling the procoagulatory effect of Anastrozole relative to ERα and ERβ expression in breast cancer cells
    Kyrtania Pather et al, 2022, Journal of Thrombosis and Thrombolysis CrossRef
17. Growth inhibitory efficacy and anti‑aromatase activity of Tabebuia avellanedae in a model for post‑menopausal Luminal A breast cancer
    Nitin Telang et al, 2019, Biomedical Reports CrossRef
18. Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Abeer J. Al-Qasem et al, 2022, npj Precision Oncology CrossRef